- RadNet's DeepHealth acquires iCAD, expanding its AI-powered breast cancer screening capabilities.
- The acquisition extends RadNet's impact to over 10 million mammograms annually across 50+ countries.
- Integration aims to improve cancer detection rates and enhance AI model performance globally.
RadNet, Inc. (RDNT, Financial), a leader in diagnostic imaging services and digital health solutions, has announced the acquisition of iCAD, Inc. (ICAD) through its subsidiary DeepHealth. This strategic acquisition aims to significantly bolster DeepHealth's capabilities in AI-powered breast cancer detection and screening solutions.
The integration of iCAD's extensive AI portfolio, which spans breast cancer detection, risk evaluation, density assessment, and arterial calcification analysis, will enhance DeepHealth's existing screening solutions. This merger is set to extend RadNet's reach to over 10 million mammograms annually, with iCAD's technology already deployed in more than 50 countries and over 1,500 healthcare provider locations globally.
Kees Wesdorp, President and CEO of RadNet’s Digital Health segment, expressed enthusiasm about the acquisition, noting the improved potential for early detection and efficient workflow management. The merger aims to address several critical challenges in breast cancer screening, particularly benefiting underserved communities with advanced diagnostic capabilities.
This acquisition is expected to accelerate the adoption of AI-powered solutions in the healthcare sector, aligning with industry trends towards AI-augmented clinical decision support systems. By combining datasets and technologies, RadNet and iCAD aim to improve cancer detection rates and enhance operational efficiency, thereby cementing RadNet's competitive position in the healthcare AI market.
